Though often seen as a minor skin condition, molluscum contagiosum can have a lasting emotional and physical impact, especially for children and their families. A newly published study in the American Journal of Clinical Dermatology brings a more human-centered lens to treatment evaluation. With Dr. Ira Thorla of DelRicht Research and LA Dermatology Associates in Baton Rouge, LA, as a contributing author, the B-SIMPLE4 study examined not only clinical outcomes but also patient-reported experiences, shifting the conversation on what meaningful progress looks like.

About the Study

B-SIMPLE4 (Berdazimer Sodium In Molluscum Patients with LEsions) was a large, randomized, controlled Phase III trial evaluating the safety and efficacy of berdazimer gel, 10.3%, compared to a vehicle gel. The study enrolled 891 participants who applied treatment once daily for 12 weeks. Uniquely, it also included Global Impression of Change scores and exit interviews, offering valuable insights into the patient and caregiver experience.

Results That Go Beyond Clearance

By Week 12, the results were compelling:

– 82% of berdazimer-treated participants reported they were “very much” or “much” improved, compared to 60% in the control group.

– Investigators reported similar findings, with 80% of berdazimer patients rated as improved versus 54% of vehicle group participants.

– Among those who experienced a ≥75% reduction in lesions, 99% reported a meaningful change.

Participants saw an average drop of 18 lesions, representing a 76% reduction, but even partial improvements were widely perceived as meaningful. The study’s patient-centered design allowed for a more nuanced understanding of what success looks like in real life.

Listening to Patients

Exit interviews conducted with 30 participants revealed that molluscum had persisted for nearly two years on average. While itching, pain, and scarring were physically uncomfortable, emotional effects, such as embarrassment and social anxiety, were most frequently cited as distressing. Despite not achieving complete lesion clearance, 26 out of 30 participants reported satisfaction with their trial experience. Of the 22 who still had lesions, 17 still described the reduction as meaningful.

Why This Matters

This study reframes how therapeutic success is measured in dermatology. It shows that patients value progress, not just perfection, especially in pediatric cases where visible symptoms affect confidence and social well-being. By including real-world patient feedback, B-SIMPLE4 offers new guidance for future treatment development, trial design, and regulatory evaluation.

Explore Dr. Ira Thorla’s Contributions in the Full Study

The full publication, A Patient-Centered Perspective of Molluscum Contagiosum as Reported by B-SIMPLE4 Clinical Trial Patients and Caregivers, is available in the American Journal of Clinical Dermatology. 

At DelRicht Research, we are proud to support investigators like Dr. Ira Thorla, whose work centers on the patient voice. With each study, we move closer to care that truly reflects the needs and experiences of those we serve.